Bioprotein obtains license from GTC Biotherapeutics
BioProtein Technologies, the biotechnology company specialising in the production of therapeutic proteins in the milk of transgenic rabbits, has entered into an important licensing agreement with GTC Biotherapeutics, the US based transgenics production company, which broadens its intellectual property position.
BioProtein Technologies, the biotechnology company specialising in the production of therapeutic proteins in the milk of transgenic rabbits, has entered into an important licensing agreement with GTC Biotherapeutics, the US based transgenics production company, which broadens its intellectual property position.
The agreement with GTC will enable BioProtein Technologies to expand its ability to develop proteins in milk, supporting its ambition to become a significant player in the area of recombinant protein manufacturing in rabbits.
Under the terms of the agreement, GTC has granted BioProtein Technologies certain rights to its European patent for the production of recombinant proteins in the milk of transgenic rabbits. These rights are primarily in the European Union, Turkey and Switzerland.
Commenting on the announcement, Marc Le Bozec, ceo of BioProtein Technologies said: 'This is a major strategic achievement for BioProtein Technologies as it reinforces our IP position in the production of recombinant proteins in the milk of transgenic rabbits, which will directly benefit our customers. I am confident that we will be able to build on the good relationship that we have developed with GTC for the future benefit of both parties.'